{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:42:32Z","timestamp":1790728952280,"version":"4.1.0"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease, is the most prevalent liver disorder worldwide. Historically, its diagnosis required biopsy, even though the procedure has a variable degree of error. Therefore, new non-invasive strategies are needed. Consequently, this article presents a thorough review of biopsy-free scoring systems proposed for the diagnosis of MAFLD. Similarly, it compares the severity of the disease, ranging from hepatic steatosis (HS) and nonalcoholic steatohepatitis (NASH) to fibrosis, by contrasting the corresponding serum markers, clinical associations, and performance metrics of these biopsy-free scoring systems. In this regard, defining MAFLD in conjunction with non-invasive tests can accurately identify patients with fatty liver at risk of fibrosis and its complications. Nonetheless, several biopsy-free scoring systems have been assessed only in certain cohorts; thus, further validation studies in different populations are required, with adjustment for variables, such as body mass index (BMI), clinical settings, concomitant diseases, and ethnic backgrounds. Hence, comprehensive studies on the effects of age, morbid obesity, and prevalence of MAFLD and advanced fibrosis in the target population are required. Nevertheless, the current clinical practice is urged to incorporate biopsy-free scoring systems that demonstrate adequate performance metrics for the accurate detection of patients with MAFLD and underlying conditions or those with contraindications of biopsy.<\/jats:p>","DOI":"10.3389\/fmed.2021.774079","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T05:33:05Z","timestamp":1642051985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["MAFLD\/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis"],"prefix":"10.3389","volume":"8","author":[{"given":"Nancy de los \u00c1ngeles","family":"Segura-Azuara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Daniel","family":"Varela-Chinchilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio A.","family":"Trinidad-Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/MEG.0000000000001235","article-title":"Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies","volume":"30","author":"Tomic","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","article-title":"Nonalcoholic fatty liver disease: pathology and pathogenesis","volume":"5","author":"Tiniakos","year":"2010","journal-title":"Annu Rev Pathol Mech Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15562\/bmj.v10i2.2359","article-title":"Rahadina A. Does nafld fibrosis score predict mortality risk among mafld patients?: a systematic review and meta-analysis","volume":"10","author":"Rahadini","year":"2021","journal-title":"Bali Med J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9181368","DOI":"10.1155\/2020\/9181368","article-title":"Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach","volume":"2020","author":"Grgurevic","year":"2020","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.3390\/ijms20205037","article-title":"Development and progression of non-alcoholic fatty liver disease: The role of advanced glycation end products","volume":"20","author":"Fernando","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000282089","article-title":"Systemic symptoms in non-alcoholic fatty liver disease","volume":"28","author":"Newton","year":"2010","journal-title":"Dig Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.21037\/hbsn.2018.12.05","article-title":"Nonalcoholic fatty liver disease (NAFLD) prevention: role of Mediterranean diet and physical activity","volume":"8","author":"Trovato","year":"2019","journal-title":"HepatoBiliary Surg Nutr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000447276","article-title":"Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, Type 2-diabetes and dysbiosis","volume":"34","author":"Scorletti","year":"2016","journal-title":"Dig Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11892-011-0190-2","article-title":"Why does NAFLD predict type 2 diabetes?","volume":"11","author":"Lattuada","year":"2011","journal-title":"Curr Diab Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","article-title":"The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA)","volume":"239","author":"Al Rifai","year":"2015","journal-title":"Atherosclerosis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What's in a name? Renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cld.740","article-title":"Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease","volume":"13","author":"Berger","year":"2019","journal-title":"Clin Liver Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3727\/105221619X15553433838609","article-title":"Nonalcoholic fatty liver disease: an update on the diagnosis","volume":"19","author":"Zhang","year":"2019","journal-title":"Gene Expr J Liver Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11695-007-9041-2","article-title":"Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass","volume":"17","author":"Arun","year":"2007","journal-title":"Obes Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicines6010041","article-title":"The epidemiology , risk profiling and diagnostic challenges of nonalcoholic fatty liver disease","author":"Iqbal","year":"2019","journal-title":"Medicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/hepr.13502","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: a targeted literature review","volume":"50","author":"Eguchi","year":"2020","journal-title":"Hepatol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts","volume":"24","author":"Papatheodoridi","year":"2019","journal-title":"Curr Pharm Des."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","article-title":"The utility of liver biopsy in 2020","volume":"36","author":"Khalifa","year":"2020","journal-title":"Curr Opin Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7671508","article-title":"Predictive value of a noninvasive serological hepatic fibrosis scoring system in cirrhosis combined with oesophageal varices","author":"Zhang","year":"2018","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut."},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/diagnostics11010098","article-title":"Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease","volume":"11","author":"Ballestri","year":"2021","journal-title":"Diagnostics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43066-020-00044-w","article-title":"Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease","volume":"10","author":"Mansour","year":"2020","journal-title":"Egypt Liver J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","author":"M\u00f3zes","year":"2021","journal-title":"Gut."},{"key":"B33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2019","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.14172","article-title":"Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population","volume":"46","author":"Yip","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080845","article-title":"Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)","volume":"8","author":"Drescher","year":"2019","journal-title":"Cells."},{"key":"B37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.21037\/atm-20-2951","article-title":"Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance","volume":"8","author":"Jeong","year":"2020","journal-title":"Ann Transl Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hep.24356","article-title":"Fatty liver index and mortality: The cremona study in the 15th year of follow-up","volume":"54","author":"Calori","year":"2011","journal-title":"Hepatology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.22845","article-title":"Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population","volume":"49","author":"Gastaldelli","year":"2009","journal-title":"HepatoSlogy."},{"key":"B43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1530\/EJE-10-1039","article-title":"Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population","volume":"164","author":"Taverna","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-230X-10-98","article-title":"A simple index of lipid overaccumulation is a good marker of liver steatosis","author":"Bedogni","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-019-01626-1","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","volume":"55","author":"Shima","year":"2020","journal-title":"J Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00535-010-0305-6","article-title":"A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease","volume":"46","author":"Sumida","year":"2011","journal-title":"J Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1007\/s11695-008-9506-y","article-title":"A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)","volume":"18","author":"Younossi","year":"2008","journal-title":"Obes Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2020-001174","article-title":"Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels","volume":"8","author":"Zheng","year":"2020","journal-title":"BMJ Open Diabetes Res Care."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","author":"Loaeza-del-Castillo","year":"2008","journal-title":"Ann Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.12659\/MSM.883601","article-title":"The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease","volume":"18","author":"Cichoz-Lach","year":"2012","journal-title":"Med Sci Monit."},{"key":"B53","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of hepamet fibrosis scoring system\u2013a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/liv.12760","article-title":"ELF score \u226598 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity","volume":"35","author":"Fagan","year":"2015","journal-title":"Liver Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jhep.2008.07.035","article-title":"Comparison of blood tests for liver fibrosis specific or not to NAFLD","volume":"50","author":"Cal\u00e8s","year":"2009","journal-title":"J Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2019","journal-title":"J Investig Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s10620-016-4079-4","article-title":"Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016","volume":"61","author":"Kaswala","year":"2016","journal-title":"Dig Dis Sci."},{"key":"B59","first-page":"661","article-title":"Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD","volume":"8","author":"Alkhouri","year":"2012","journal-title":"Gastroenterol Hepatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1365-2036.2010.04480.x","article-title":"A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients","volume":"32","author":"Anty","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-3-030-11748-1_16","article-title":"Emerging circulating biomarkers for the diagnosis and assessment of treatment responses in patients with hepatic fat accumulation, nash and liver fibrosis. Transl res methods diabetes, obesity, nonalcoholic fat liver dis a focus early phase","author":"Iruarrizaga-Lejarreta","year":"2019","journal-title":"Clin Drug Dev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J Proteome Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2013.12.009","article-title":"A population-based study on the prevalence of NASH using scores validated against liver histology","volume":"60","author":"Hyysalo","year":"2014","journal-title":"J Hepatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2017.08.024","article-title":"Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis","volume":"16","author":"Verhaegh","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/liv.14640","article-title":"Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease","volume":"40","author":"Nascimbeni","year":"2020","journal-title":"Liver Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9112458","article-title":"Significance of Simple Steatosis: an update on the clinical and molecular evidence","volume":"9","author":"Mazzolini","year":"2020","journal-title":"Cells."},{"key":"B68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/hep.26661","article-title":"Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease","volume":"59","author":"Moylan","year":"2014","journal-title":"Hepatology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA-J Am Med Assoc."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","article-title":"Significant correlations between severe fatty liver and risk factors for metabolic syndrome","volume":"22","author":"Hsiao","year":"2007","journal-title":"J Gastroenterol Hepatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.dld.2010.01.016","article-title":"From the metabolic syndrome to NAFLD or vice versa?","volume":"42","author":"Vanni","year":"2010","journal-title":"Dig Liver Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-981-10-8684-7_4","article-title":"Chemokines and chemokine receptors in the development of NAFLD","volume":"1061","author":"Roh","year":"2018","journal-title":"Adv Exp Med Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0174717","article-title":"Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis","volume":"12","author":"Yoo","year":"2017","journal-title":"PLoS ONE."},{"key":"B74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/apt.14967","article-title":"Liver fat scores predict liver disease mortality in the United States population","volume":"48","author":"Unalp-Arida","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/07853890.2021.1943514","article-title":"Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999\u20132016","volume":"53","author":"Lee CO Li","year":"2021","journal-title":"Ann Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jgh.13814","article-title":"Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes","volume":"33","author":"Svikl\u0101ne","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01419-z","article-title":"Association between the alanine aminotransferase\/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study","volume":"19","author":"Zou","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrgastro.2016.104","article-title":"Obesity: Metabolically healthy obesity and NAFLD","volume":"13","author":"Targher","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1097\/CM9.0000000000000503","article-title":"Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome","volume":"132","author":"Chen L","year":"2019","journal-title":"Chin Med J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/DMSO.S189544","article-title":"The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea national health and nutrition examination survey 2010\u20132011","volume":"12","author":"Khang","year":"2019","journal-title":"Diabetes, Metab Syndr Obes Targets Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-53947-z","article-title":"The impact of NAFLD and waist circumference changes on diabetes development in prediabetes subjects","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J Gastroenterol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/HJH.0000000000001204","article-title":"Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies","volume":"35","author":"Bonnet","year":"2017","journal-title":"J Hypertens."},{"key":"B86","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4254\/wjh.v12.i4.149","article-title":"Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population","volume":"12","author":"Lind","year":"2020","journal-title":"World J Hepatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/MD.0000000000001682","article-title":"Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese","author":"Huang","year":"2015","journal-title":"Medicine."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2261-5-26","article-title":"The \u201clipid accumulation product\u201d performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison","volume":"5","author":"Kahn","year":"2005","journal-title":"BMC Cardiovasc Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-017-0206-2","article-title":"Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults","volume":"14","author":"Dai","year":"2017","journal-title":"Nutr Metab."},{"key":"B90","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3345\/kjp.2019.00248","article-title":"Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity","volume":"62","author":"\u00d6zcabi","year":"2019","journal-title":"Korean J Pediatr."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","article-title":"Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future","volume":"38","author":"Ara\u00fajo","year":"2018","journal-title":"Liver Int."},{"key":"B94","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/hep4.1637","article-title":"Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes","volume":"5","author":"Ishiba","year":"2021","journal-title":"Hepatol Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00535-017-1355-9","article-title":"Simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis","volume":"53","author":"Okanoue","year":"2018","journal-title":"J Gastroenterol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00535-017-1414-2","article-title":"Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods","volume":"53","author":"Yoneda","year":"2018","journal-title":"J Gastroenterol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124337","article-title":"Epidemiology: pathogenesis, and diagnostic strategy of diabetic liver disease in Japan","volume":"21","author":"Sumida","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4172\/2161-069X.1000221","article-title":"A caution in the use of the NAFIC scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis","volume":"4","author":"Nakamura","year":"2014","journal-title":"J Gastrointest Dig Syst."},{"key":"B99","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12072-019-09934-7","article-title":"Serum ferritin as a biomarker for NAFLD: ready for prime time?","volume":"13","author":"Shah","year":"2019","journal-title":"Hepatol Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/1354750X.2018.1425915","article-title":"New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"23","author":"Tada","year":"2018","journal-title":"Biomarkers."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s11695-020-04509-0","article-title":"performance of noninvasive liver fibrosis scores in the morbid obese patient, same scores but different thresholds","volume":"30","author":"Meneses","year":"2020","journal-title":"Obes Surg."},{"key":"B102","first-page":"477","article-title":"A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH","volume":"101","author":"Kruger","year":"2011","journal-title":"South African Med J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2","DOI":"10.15761\/IMM.1000130","article-title":"Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD","author":"Sumida","year":"2015","journal-title":"Integr Mol Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"154028","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari","year":"2020","journal-title":"Metabolism."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.3748\/wjg.v21.i11.3223","article-title":"Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?","volume":"21","author":"Sanal","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1111\/febs.15322","article-title":"Resistin in metabolism, inflammation, and disease","volume":"287","author":"Tripathi","year":"2020","journal-title":"FEBS J."},{"key":"B107","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12691\/jnh-7-2-1","article-title":"Nutrient-Adipokine Interaction in NAFLD: A Review","volume":"7","author":"Grover","year":"2019","journal-title":"World J Nutr Heal."},{"key":"B108","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis : Natural history of non-alcoholic fatty liver disease ( NAFLD ) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/ijms21041219","article-title":"multifaceted physiological roles of adiponectin in inflammation and diseases","volume":"21","author":"Choi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.clinbiochem.2006.12.010","article-title":"Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation","volume":"40","author":"Yagmur","year":"2007","journal-title":"Clin Biochem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-06-0231","article-title":"Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors","volume":"12","author":"De Bruin","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cca.2014.03.018","article-title":"The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"433","author":"Miyasato","year":"2014","journal-title":"Clin Chim Acta."},{"key":"B113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/0004563218796259","article-title":"Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease","volume":"56","author":"Chang","year":"2019","journal-title":"Ann Clin Biochem"},{"key":"B114","doi-asserted-by":"publisher","first-page":"6036904","DOI":"10.1155\/2020\/6036904","article-title":"Serum golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis","volume":"2020","author":"Wang","year":"2020","journal-title":"Dis Markers."},{"key":"B115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0040-1713006","article-title":"Noninvasive tests in the assessment of NASH and NAFLD fibrosis: now and into the future","volume":"40","author":"Adams","year":"2020","journal-title":"Semin Liver Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MD.0000000000014324","article-title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis","author":"Dai","year":"2019","journal-title":"Medicine."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.202001495R","article-title":"Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD","author":"Muyyarikkandy","year":"2020","journal-title":"FASEB J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/MCG.0000000000001284","article-title":"Loomba R. The role of noninvasive tests for differentiating NASH from NAFL and diagnosing advanced fibrosis among patients with NAFLD","volume":"54","author":"Balakrishnan","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/liv.13451","article-title":"Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis","volume":"37","author":"Traussnigg","year":"2017","journal-title":"Liver Int."},{"key":"B120","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5152\/tjg.2018.17330","article-title":"Liver fibrosis","volume":"29","author":"Aydin","year":"2018","journal-title":"Turkish J Gastroenterol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis : mechanistic concepts and therapeutic perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43066-020-00043-x","article-title":"Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult","volume":"10","author":"Paul","year":"","journal-title":"Egypt Liver J."},{"key":"B123","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.trsl.2020.11.003","article-title":"Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets","volume":"231","author":"Miele","year":"2021","journal-title":"Transl Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/bloodadvances.2017010868","article-title":"Platelet TGF-\u03b21 deficiency decreases liver fibrosis in a mouse model of liver injury","volume":"2","author":"Ghafoory","year":"2018","journal-title":"Blood Adv."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-020-01400-1","article-title":"Evaluation of NAFLD and fibrosis in obese patients-a comparison of histological and clinical scoring systems","volume":"20","author":"Schmitz","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1053\/j.gastro.2013.08.025","article-title":"NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials?","volume":"145","author":"Gawrieh","year":"2013","journal-title":"Gastroenterology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ctg.0000000000000165","article-title":"Accuracy of noninvasive fibrosis scoring systems in african american and white patients with nonalcoholic fatty liver disease","volume":"11","author":"Marella","year":"2020","journal-title":"Clin Transl Gastroenterol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.dld.2017.05.002","article-title":"AST to platelet ratio index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"49","author":"Peleg","year":"2017","journal-title":"Dig Liver Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology."},{"key":"B130","doi-asserted-by":"publisher","first-page":"101528","DOI":"10.1016\/j.clinre.2020.08.006","article-title":"Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease","author":"Huang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1665-2681(19)31004-X","article-title":"Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population","volume":"12","author":"P\u00e9rez-Guti\u00e9rrez","year":"2013","journal-title":"Ann Hepatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jmii.2019.09.002","article-title":"Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C","volume":"53","author":"Cheng","year":"2020","journal-title":"J Microbiol Immunol Infect."},{"key":"B133","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/jhep.2002.36128","article-title":"Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model","volume":"36","author":"Forns","year":"2002","journal-title":"Hepatology."},{"key":"B134","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4318\/tjg.2011.0213","article-title":"AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"22","author":"G\u00fczelbulut","year":"2011","journal-title":"Turkish J Gastroenterol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tgh.2019.11.14","article-title":"Non-invasive diagnosis: Non-alcoholic fatty liver disease and alcoholic liver disease","author":"Altamirano","year":"2020","journal-title":"Transl Gastroenterol Hepatol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ctg.0000000000000066","article-title":"Multicenter validation study of a diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness","volume":"10","author":"Liebig","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12020-020-02319-z","article-title":"Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease","volume":"69","author":"Sun","year":"2020","journal-title":"Endocrine."},{"key":"B138","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s11695-014-1235-9","article-title":"The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD","volume":"24","author":"Naveau","year":"2014","journal-title":"Obes Surg."},{"key":"B140","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.aohep.2020.08.066","article-title":"Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population","volume":"19","author":"Zambrano-Huailla","year":"2020","journal-title":"Ann Hepatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1007\/s10620-020-06821-2","article-title":"Hepamet fibrosis score in nonalcoholic fatty liver disease patients in mexico: lower than expected positive predictive value","volume":"66","author":"Higuera-de-la-Tijera","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B142","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/apt.15529","article-title":"Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and enhanced liver fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres","volume":"50","author":"Guillaume","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.3390\/ijerph16193570","article-title":"Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD","volume":"16","author":"Kup\u010dov\u00e1","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"B145","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/hepr.13495","article-title":"Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"50","author":"Inadomi","year":"2020","journal-title":"Hepatol Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1177\/2050640619865133","article-title":"Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Staufer","year":"2019","journal-title":"United Eur Gastroenterol J."},{"key":"B148","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0399-8320(08)73992-7","article-title":"FibroMeters: a family of blood tests for liver fibrosis","volume":"32","author":"Cal\u00e8s","year":"2008","journal-title":"Gastroenterol Clin Biol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/j.1478-3231.2010.02314.x","article-title":"Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease","volume":"30","author":"Cal\u00e8s","year":"2010","journal-title":"Liver Int."},{"key":"B151","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4254\/wjh.v7.i4.638","article-title":"Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease","volume":"7","author":"Papagianni","year":"2015","journal-title":"World J Hepatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"259","DOI":"10.37349\/emed.2020.00018","article-title":"The diagnostic conundrum in non-alcoholic fatty liver disease","volume":"1","author":"Rosato","year":"2020","journal-title":"Explor Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/flgastro-2017-100865","article-title":"Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent","volume":"9","author":"De Silva","year":"2018","journal-title":"Frontline Gastroenterol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1586\/14737159.7.5.481","article-title":"FibroMAXTM: towards a new universal biomarker of liver disease?","volume":"7","author":"Morra","year":"2007","journal-title":"Expert Rev Mol Diagn."},{"key":"B155","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MEG.0b013e3283464111","article-title":"Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity","volume":"23","author":"Lassailly","year":"2011","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/apt.13770","article-title":"Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference","volume":"44","author":"Munteanu","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B157","doi-asserted-by":"crossref","DOI":"10.23736\/S1121-421X.20.02746-4","article-title":"Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease","author":"Lardi","year":"2020","journal-title":"Minerva Gastroenterol Dietol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/jcm10112415","article-title":"Fibrotest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"10","author":"Vali","year":"2021","journal-title":"J Clin Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"262","DOI":"10.15406\/ghoa.2019.10.00392","article-title":"The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)","volume":"10","author":"Yousaf","year":"2019","journal-title":"Gastroenterol Hepatol Open Access."},{"key":"B160","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cld.2017.08.006","article-title":"The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom","volume":"22","author":"Gunn","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B161","doi-asserted-by":"publisher","first-page":"899","DOI":"10.5604\/01.3001.0012.7188","article-title":"The evolving role of liver biopsy in non-alcoholic fatty liver disease","volume":"17","author":"Arab","year":"2018","journal-title":"Ann Hepatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/hep4.1055","article-title":"Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation","volume":"1","author":"Brunt","year":"2017","journal-title":"Hepatol Commun."},{"key":"B163","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/RMHP.S285880","article-title":"Criteria guide the subtyping of patients with fatty liver disease","volume":"14","author":"Huang","year":"2021","journal-title":"Risk Manag Healthc Policy."},{"key":"B164","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2016.0049","article-title":"Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment","volume":"22","author":"Oh","year":"2016","journal-title":"Clin Mol Hepatol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0214436","article-title":"Non-invasive assessment of NAFLD as systemic disease\u2014a machine learning perspective","volume":"14","author":"Canbay","year":"2019","journal-title":"PLoS ONE."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314472.321","article-title":"Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent","volume":"9","author":"De Silva","year":"2017","journal-title":"Frontline Gastroenterol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"\u00d6nnerhag","year":"2019","journal-title":"Scand J Gastroenterol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","article-title":"Liver fibrosis in overweight patients","volume":"118","author":"Ratziu","year":"2000","journal-title":"Gastroenterology."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90648-y","article-title":"Age-adjusted cut-off values of lipid accumulation product (LAP) for predicting hypertension","volume":"11","author":"Kaneva","year":"2021","journal-title":"Sci Rep."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells."},{"key":"B171","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/bmj.i4428","article-title":"Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance","author":"Glen","year":"2016","journal-title":"Br Med J."},{"key":"B172","volume-title":"National Institute for Health and Care Excellence| NICE Guidance","year":"2016"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/dom.14322","article-title":"Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review","volume":"23","author":"Cariou","year":"2021","journal-title":"Diabetes, Obes Metab."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.774079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T20:11:39Z","timestamp":1674418299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.774079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":173,"alternative-id":["10.3389\/fmed.2021.774079"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.774079","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"774079"}}